ClinicalTrials.gov
ClinicalTrials.gov Menu

Percutaneous Needle Tenotomy (PNT) Versus Platelet Rich Plasma (PRP) With PNT in the Treatment of Chronic Tendinosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01833598
Recruitment Status : Active, not recruiting
First Posted : April 17, 2013
Last Update Posted : January 16, 2018
Sponsor:
Information provided by (Responsible Party):
Hospital for Special Surgery, New York

Brief Summary:

Tendinopathy is a clinical syndrome of chronic pain and tendon degeneration that impairs a person's ability to perform daily activities and recreation. Traditional conservative treatments include activity modification, exercises, ice/heat, and medications and corticosteroid injection. A newer treatment is percutaneous needle tenotomy (PNT), in which the affected area is repetitively needled to disrupt pathological tissue and induce bleeding. This turns a nonhealing chronic injury into an acute injury with enhanced healing capability. Another is Platelet Rich Plasma (PRP), whereby patients' own platelets are injected into the affected area, also activating growth factors. There has been promising research in these tendinopathy treatments but more research is needed.

The investigators plan to expand on prior studies to identify a reproducible and efficacious treatment for chronic tendinopathy to reduce pain and improve function and quality of life. Our goal in this study is to assess the efficacy of ultrasound guided (USG) PNT versus PNT with peritendinous PRP as a treatment for chronic tendinopathy.


Condition or disease Intervention/treatment Phase
Chronic Tendinopathy Procedure: PNT + PRP Procedure: PNT alone Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: The Efficacy of Ultrasound Guided Percutaneous Needle Tenotomy (PNT) Versus Platelet Rich Plasma (PRP) With PNT in the Treatment of Chronic Tendinosis
Actual Study Start Date : September 2012
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tendinitis

Arm Intervention/treatment
Active Comparator: PNT + PRP
percutaneous needle tenotomy with peritendinous platelet-rich plasma injection
Procedure: PNT + PRP
The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
Other Name: percutaneous needle tenotomy with peritendinous platelet-rich plasma injection

Active Comparator: PNT alone
percutaneous needle tenotomy alone
Procedure: PNT alone
The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
Other Name: percutaneous needle tenotomy alone




Primary Outcome Measures :
  1. Pain [ Time Frame: Week 2 ]
  2. Pain [ Time Frame: Week 4 ]
  3. Pain [ Time Frame: Week 6 ]
  4. Pain [ Time Frame: Week 8 ]
  5. Pain [ Time Frame: Week 12 ]

Secondary Outcome Measures :
  1. Activity Level [ Time Frame: Week 2 ]
    Function, sleep, general well-being, return to normal activities, work, sports and reduction in pain medication usage.

  2. Activity Level [ Time Frame: Week 4 ]
    Function, sleep, general well-being, return to normal activities, work, sports and reduction in pain medication usage.

  3. Activity Level [ Time Frame: Week 6 ]
    Function, sleep, general well-being, return to normal activities, work, sports and reduction in pain medication usage.

  4. Activity Level [ Time Frame: Week 8 ]
    Function, sleep, general well-being, return to normal activities, work, sports and reduction in pain medication usage.

  5. Activity Level [ Time Frame: Week 12 ]
    Function, sleep, general well-being, return to normal activities, work, sports and reduction in pain medication usage.

  6. Complications [ Time Frame: Week 2 ]
    bleeding, infection, tendon rupture, allergic reaction, paralysis, or stroke

  7. Complications [ Time Frame: Weeks 4 ]
    bleeding, infection, tendon rupture, allergic reaction, paralysis, or stroke

  8. Complications [ Time Frame: Weeks 6 ]
    bleeding, infection, tendon rupture, allergic reaction, paralysis, or stroke

  9. Complications [ Time Frame: Weeks 8 ]
    bleeding, infection, tendon rupture, allergic reaction, paralysis, or stroke

  10. Complications [ Time Frame: Weeks 12 ]
    bleeding, infection, tendon rupture, allergic reaction, paralysis, or stroke



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • aged 18-100 years
  • pain (≥ 5/10 pain on the VAS) that is a direct result of tendinosis as determined by history of injury and study team member physician's best judgment and review of medical records, imaging studies, etc.
  • Tendinosis will be confirmed by clinical and ultrasonographic examination by the PI
  • ≥3 months of pain after injury that has failed conservative treatments or after corticosteroid (CSI) (must be 3 months after CSI to avoid theoretical tendon rupture)

Exclusion Criteria:

  • taking coumadin or other anti-coagulant or anti-platelet medication
  • known coagulopathy or bleeding dyscrasia
  • current or recent fluoroquinolone prescription
  • prior PNT or PRP for the affected tendon(s)
  • known systemic illness such as vasculitis, an autoimmune or an inflammatory disease, or uncontrolled diabetes
  • presence of other musculoskeletal injury or tendon rupture in the region
  • currently are or plan to become pregnant during the study.

    • Patients taking aspirin or NSAIDs are not excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01833598


Locations
United States, New York
Hospital for Special Surgery
New York, New York, United States, 10021
Department of Rehabilitation Medicine, Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Sponsors and Collaborators
Hospital for Special Surgery, New York
Investigators
Principal Investigator: Jonathan Kirschner, MD Hospital for Special Surgery, New York

Publications:

Responsible Party: Hospital for Special Surgery, New York
ClinicalTrials.gov Identifier: NCT01833598     History of Changes
Other Study ID Numbers: GCO 12-0656
HSS 2015-189
First Posted: April 17, 2013    Key Record Dates
Last Update Posted: January 16, 2018
Last Verified: January 2018

Keywords provided by Hospital for Special Surgery, New York:
Chronic tendinopathy
platelet rich plasma
tendonitis
percutaneous tendon tenotomy
pain
shoulder
knee
ankle
foot

Additional relevant MeSH terms:
Tendinopathy
Muscular Diseases
Musculoskeletal Diseases
Tendon Injuries
Wounds and Injuries